Mirum Pharmaceuticals SVP Global Controller Howe Jolanda sold 658 shares at $100 per share on September 2, 2026. Following the transaction, Howe Jolanda owned 616 shares. The transaction matters to investors because it identifies both the sale price and the remaining shareholding of a senior company executive.
Key Highlights
- Howe Jolanda serves as Mirum Pharmaceuticals’ SVP, GLOBAL CONTROLLER.
- Ownership following the transaction stood at 616 shares.
- The sale took place on September 2, 2026.
Howe Jolanda, the company’s SVP, GLOBAL CONTROLLER, sold 658 Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) shares at $100 per share. The transaction left Howe Jolanda with ownership of 616 shares.
Insider Sale Details
Howe Jolanda sold the 658 shares on September 2, 2026, at a price of $100 per share. The transaction involved Mirum Pharmaceuticals shares and was made by the company’s SVP, GLOBAL CONTROLLER. That figure represents the shares held following the reported transaction. The sale price was $100 per share. The transaction date was September 2, 2026.
FAQs
Q: How many Mirum Pharmaceuticals shares did Howe Jolanda sell?
A: Howe Jolanda sold 658 Mirum Pharmaceuticals shares in the reported transaction. The filing states that the shares were sold at $100 per share and identifies her as the company’s SVP, GLOBAL CONTROLLER.
Q: How many shares did Howe Jolanda own after the MIRM transaction?
A: Howe Jolanda owned 616 Mirum Pharmaceuticals shares following the reported transaction. The filing states that the transaction involved a sale of 658 shares at $100 per share.
Q: When did the Mirum Pharmaceuticals insider sale occur?
A: The Mirum Pharmaceuticals share sale took place on September 2, 2026. Howe Jolanda sold 658 shares at $100 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.